Medtronic (MDT) Announced Q3 2026 Earnings on February 17, 2026, Reporting Revenue of $9 Billion

Medtronic reported "revenue of $9 billion" for the third quarter of fiscal year 2026, which "grew 8.7% reported and 6% organic". The company delivered "adjusted operating profit of 2.2billion" for the quarter, with an "adjusted operating margin of 24.1.  Adjusted EPS for the quarter was 1.36," which management noted was a "beat of $0.03".

Business updates focused on four "generational growth drivers," including the Cardiac Ablation Solutions business where "PFA grew nearly 200% worldwide". Management highlighted that the "Hugo robot received FDA clearance for urologic surgical procedures," and they "completed our first cases at Cleveland Clinic". In Neuroscience, the company "secured FDA clearance for our Stealth AXiS Surgical System," describing it as a "new transformative platform that unifies AI-powered planning, robotics and navigation".

Looking ahead, Medtronic is "reiterating fiscal '26 organic revenue growth guidance of approximately 5.5%". The company is "maintaining our fiscal '26 EPS guidance in the range of $5.62 to $5.66" and maintains their "expectation for high single-digit EPS growth in fiscal year '27"